MMP-2 Inhibitor I
(Synonyms: Matrix Metalloproteinase-2 Inhibitor I,cis-9-Octadecenoyl-N-hydroxylamide,Oleylhydroxamate) 目录号 : GC17738A selective MMP-2 inhibitor
Cas No.:10335-69-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MMP-2 Inhibitor I, a hydroxamate-based, long-chain fatty acid, is a reversible inhibitor of matrix metalloproteinase (MMP)-2.
Matrix metalloproteinases (MMPs) have been involved in the degradation of extracellular matrix. MMPs contribute to long-term remodeling processes such as embryogenesis, tumor invasion, inflammation, angiogenesis, and wound healing. MMP-2, also known as gelatinase A or type IV collagenase, has been involved in regulating diverse cellular functions independent of its action on the extracellular matrix, including vascular tone, platelet aggregation, and mediation of the acute mechanical dysfunction of the heart immediately after ischemia and reperfusion [2]. Up-regulation of MMP-2 has been associated with tumor invasion and metastasis [3].
MMP-2 Inhibitor I inhibited the activity of matrix metalloproteinase (MMP)-2 with the Ki value of 1.6 μM [1]. MMP-2 Inhibitor I attenuated cancer cell migration [3]. MMP-2 Inhibitor I had also been used to preserve blood-brain barrier function in a Wistar rat model of pneumococcal meningitis [4].
References:
[1] Berton A, Rigot V, Huet E, et al. Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids[J]. Journal of Biological Chemistry, 2001, 276(23): 20458-20465.
[2] Wang W, Schulze C J, Suarez-Pinzon W L, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury[J]. Circulation, 2002, 106(12): 1543-1549.
[3] Emmert-Buck M R, Roth M J, Zhuang Z, et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples[J]. The American journal of pathology, 1994, 145(6): 1285.
[4] Barichello T, Generoso J S, Michelon C M, et al. Inhibition of matrix metalloproteinases-2 and-9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats[J]. Experimental Biology and Medicine, 2014, 239(2): 225-231.
| Cas No. | 10335-69-0 | SDF | |
| 别名 | Matrix Metalloproteinase-2 Inhibitor I,cis-9-Octadecenoyl-N-hydroxylamide,Oleylhydroxamate | ||
| 化学名 | N-hydroxy-9Z-octadecenamide | ||
| Canonical SMILES | ONC(CCCCCCC/C=C\CCCCCCCC)=O | ||
| 分子式 | C18H35NO2 | 分子量 | 297.5 |
| 溶解度 | ≤50mg/ml in ethanol;50mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C; protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3613 mL | 16.8067 mL | 33.6134 mL |
| 5 mM | 0.6723 mL | 3.3613 mL | 6.7227 mL |
| 10 mM | 0.3361 mL | 1.6807 mL | 3.3613 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet